NEW YORK, Nov. 15, 2012 /PRNewswire/ -- Alliqua, Inc. (OTCQB:ALQA) ("Alliqua" or the "Company"), an advanced biopharmaceutical company focused on the development, manufacturing and distribution of proprietary transdermal wound care and drug delivery technologies, today announced the appointment of Joseph Laudano, Pharm.D. to the newly created position of Vice President, Medical Affairs to support the market expansion of Alliqua's SilverSeal® products as well as other future clinical developments. Dr. Laudano will lead the development of a medical affairs team at Alliqua as the company now begins to step up the marketing efforts for our proprietary 510K FDA approved SilverSeal® hydrogels for wound care. He will also play a key role in the planning and clinical development of our platform for transdermal drug delivery
Commenting on the appointment, James Sapirstein, CEO of Alliqua stated, "We are very pleased to have an industry veteran of such high caliber join our team here at Alliqua. One of my primary near term goals as CEO of this company is to put the right people in place that can deliver on the rich potential of our proprietary technology as well as our future strategic plans. Joe has extensive experience in some key therapeutic areas such as dermatology and infectious diseases, which I believe align nicely with Alliqua's future needs as we build this organization."
Dr. Laudano joins Alliqua with more than twenty five years of experience in the pharmaceutical industry including four years as Senior Director of Medical Affairs at Forest Research Institute, a subsidiary of Forest Labs, and twenty years at Roche Laboratories. As Product Director at Roche he was responsible for strategic/tactical planning, business development, marketing and promotional activities for the diversified product portfolio which was comprised of 16 different brands including Xenical, Rocephin and Accutane. He was also part of the team that launched the Roche Dermatologics division at Roche which was dedicated to the development and commercialization of systemic and topical retinoids along with other compounds. He has extensive experience in Medical Affairs and product development, particularly with antimicrobial and dermatologic compounds, which will be critical to Alliqua as we move forward with the science to support its transdermal drug delivery platform and other future endeavors.
Commenting on his new position, Dr. Laudano added, "I am thrilled to become a part of this exciting organization which I believe is entering a tremendous new phase of growth. Having spent the better part of my career working with infectious disease products, I am very impressed with the data which sets SilverSeal apart from other hydrogel products. There are numerous studies supporting the efficacy of silver dressings in wound management. Silver has broad spectrum activity against bacteria including MRSA, Pseudomonas, and other antimicrobial-resistant bacteria. Based on this activity and with the increase of infections more resistant to antibiotic treatments, dressings like our SilverSeal® hydrogels are perfectly positioned to capitalize on the growing need in the medical marketplace for alternatives for the management of open wounds in support of antimicrobial stewardship programs."
About Alliqua, Inc.
Alliqua, Inc. (ALQA) ("Alliqua") is a biopharmaceutical company focused on the development, manufacturing and distribution of our proprietary transdermal wound care and drug delivery technologies. Alliqua's leading technology platform produces hydrogels, a three dimensional cross-linked network of water soluble polymers capable of numerous chemical configurations. We currently market our new line of 510K FDA approved hydrogel products for wound care under our SilverSeal® brand. Due to our electron beam production process at our 16,000 square foot GMP manufacturing facility, we can aggressively develop and custom manufacture a wide variety of hydrogels. Our hydrogels can be customized for various transdermal applications to address market opportunities in the treatment of wounds such as diabetic ulcers, as well as the delivery of numerous drugs or other agents for the pharmaceutical and cosmetic industries. By using our drug delivery platform in combination with certain drugs, pharmaceutical companies can increase patient compliance as well as potentially extend the life of valuable drug patents. For additional information, please visit www.alliqua.com. To receive future press releases via email, please visit: http://alliqua.com/index.php?page=investor-alerts.
Any statements contained in this press release regarding our ongoing research and development and the results attained by us to-date have not been evaluated by the Food and Drug Administration.
Legal Notice Regarding Forward-Looking Statements
This release contains forward-looking statements. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties outside of the our control that can make such statements untrue, including, but not limited to, inadequate capital, adverse economic conditions, intense competition, lack of meaningful research results, entry of new competitors and products, adverse federal, state and local government regulation, termination of contracts or agreements, technological obsolescence of our products, technical problems with our research and products, price increases for supplies and components, inability to carry out research, development and commercialization plans, loss or retirement of key executives and research scientists and other specific risks. We currently have no commercial products intended to diagnose, treat, prevent or cure any disease. The statements contained in this press release regarding our ongoing research and development and the results attained by us to-date have not been evaluated by the Food and Drug Administration. There can be no assurance that further research and development, and/or whether clinical trial results, if any, will validate and support the results of our preliminary research and studies. Further, there can be no assurance that the necessary regulatory approvals will be obtained or that we will be able to develop new products on the basis of our technologies. In addition, other factors that could cause actual results to differ materially are discussed in our Annual Report on Form 10-K filed with the SEC on March 29, 2012 and our most recent Form 10-Q filings with the SEC. Investors and security holders are urged to read these documents free of charge on the SEC's web site at www.sec.gov. We undertake no obligation to publicly update or revise our forward-looking statements as a result of new information, future events or otherwise.
SOURCE Alliqua, Inc.